# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT03273465 (Continued)

# Inclusion criteria

- Ability to understand and willingness to sign written informed consent document, including willingness to accept risk of unrelated donor stool
- Ability to swallow oral medications

# Exclusion criteria

- Severe, uncontrolled UC
- Active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- Delayed gastric emptying syndrome
- Known chronic aspiration
- History of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
- Pregnancy and lactation
- Inability to swallow pills

# Interventions

# Experimental arm

- FMT capsules

# Control arm

- Placebo capsules

# Outcomes

# Primary outcome

- UC remission (SCCAI < 3) at week 12

# Secondary outcomes

- Improvement in UC symptoms (based on SCCAI) at week 12
- Improvement in UC endoscopic score at week 12, and months 6 and 12
- Markers of inflammation (CRP, WBC, ANC, stool calprotectin) at week 12, and months 6 and month 12
- Change in gut microbiome (diversity and variability) at week 12, and months 6 and month 12
- Use of treatments for UC (e.g. glucocorticoids, immunosuppressive therapy (e.g. azathioprine), or TNF antagonists) at months 6 and 12
- Extra-intestinal disease manifestations at months 6 and 12

# Starting date

27 March 2017

# Contact information

Assaf-Harofeh Medical Center, Zerifin, Israel, 70300

# Notes

Phase 2 trial

# NCT03483246

# Study name

Impact of fecal microbiota transplantation in ulcerative colitis (REBALANCE-UC)

# Methods

RCT conducted in France

# Participants

# Inclusion criteria

- Age ≥ 18 to < 75 years
- UC (according to the Lennard Jones criteria) diagnosed for ≥ 3 months and:

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.